文献速递外周动脉疾病

膝下多节段动脉病变:腔内治疗与旁路手术在CLTI中的结果相似

Endovascular Therapy Provides Similar Results of Bypass Graft Surgery in the Treatment of Infrainguinal Multilevel Arterial Disease in Patients with Chronic Limb-Threatening Ischemia in All GLASS Stages.
PubMed 文献 · Ann Vasc Surg · 2020-04-25

单中心回顾性研究纳入153例慢性肢体威胁性缺血(CLTI)患者,比较股腘+膝下动脉腔内血管成形/支架(PTA/S,105例)与远端旁路移植(BGS,48例)的结果。36个月保肢率BGS 53.3% vs PTA/S 59.7%(P=0.24),生存率73.4% vs 61.3%(P=0.25),GLASS III期亚组保肢率亦无显著差异。

要点

  • PTA/S与BGS在CLTI合并股腘+膝下动脉病变中保肢和生存结果相似
  • GLASS III期复杂病变亚组两种术式36个月保肢率无显著差异
  • 流出道差是所有腔内治疗患者截肢的危险因素,糖尿病是GLASS III期腔内患者截肢危险因素

核心结论

  • PTA/S与BGS在CLTI合并股腘和膝下动脉病变中提供相似的保肢和生存结果,即使对广泛复杂病变(GLASS III期)亦然。

研究设计与样本

  • 单中心回顾性研究,2011至2017年共审查668例CLTI血运重建手术。
  • 153例合并股腘和膝下动脉病变的CLTI患者纳入分析,其中BGS组48例(使用自体静脉),PTA/S组105例(单次手术完成)。
  • 对复杂广泛动脉病变(GLASS III期)患者进行亚组分析,主要结局为保肢率和生存率。

主要发现

  • 平均随访21.4个月。
  • BGS组36个月生存率73.4%,PTA/S组61.3%(P=0.25)。
  • 36个月累积保肢率BGS组53.3%,PTA/S组59.7%(P=0.24)。
  • GLASS III期患者36个月保肢率PTA/S组54.4%,BGS组50.2%(P=0.29)。
  • 多因素分析显示流出道差(所有腔内治疗患者)和糖尿病(GLASS III期腔内治疗患者)是截肢的危险因素。

临床怎么用

  • 对于CLTI合并股腘和膝下动脉病变,PTA/S可作为BGS的替代选择,保肢和生存结果相似。
  • GLASS III期复杂病变患者选择术式时,两种方法均可考虑,需结合患者特征和流出道情况个体化决策。

局限性

  • 单中心回顾性研究,可能存在选择偏倚。
  • PTA/S组患者年龄更大,女性、糖尿病和慢性肾脏病比例更高;BGS组吸烟更常见。
  • 样本量有限,尤其BGS组仅48例。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Extensive infrainguinal arterial disease still pose a challenge for technical and clinical success of percutaneous angioplasty. The purpose of this study was to compare the results of concomitant femoropopliteal and infrapopliteal percutaneous angioplasty/stenting (PTA/S) with distal bypass graft surgery (BGS) in patients with chronic limb-threatening ischemia (CLTI). METHOD: In a single-center retrospective investigation between 2011 and 2017, 668 revascularization procedures for CLTI were reviewed. Concomitant femoropopliteal and infrapopliteal disease was identified in 153 CLTI patients, treated with BGS (48) using autogenous veins as substitute or PTA/S in a single procedure (105). A subgroup of patients with complex, extensive arterial lesions (GLASS stage III) received additional analysis. Primary outcomes were limb salvage and survival. RESULTS: The mean follow-up time was 21.4 months. Patients treated with PTA/S were significantly older and with predominance of females, diabetes and chronic kidney disease. Smoking was more common in patients treated with BGS. The BGS group showed a 36-month survival rate of 73.4%, whereas the PTA/S group presented a survival of 61.3% in the same interval (P = 0.25). The 36-month cumulative limb salvage rate was 53.3 and 59.7% for BGS and PTA/S, respectively (P = 0.24). For GLASS stage III patients, 36-month limb salvage rates were 54.4% for the PTA/S group and 50.2% for the BGS group (P = 0.29). Multivariate analysis pointed poor runoff status (all endovascular patients) and diabetes (GLASS III endovascular patients) as risk factors for limb loss. CONCLUSION: PTA/S and BGS presented similar results of limb salvage and survival in the treatment of concomitant femoropopliteal and infrapopliteal arterial disease in patients with CLTI, even for patients with extensive and complex arterial disease.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Casella IB, Sartori CH, Faustino CB, et al. Endovascular Therapy Provides Similar Results of Bypass Graft Surgery in the Treatment of Infrainguinal Multilevel Arterial Disease in Patients with Chronic Limb-Threatening Ischemia in All GLASS Stages. Ann Vasc Surg. 2020. PMID: 32339688. doi:10.1016/j.avsg.2020.04.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。